Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: A successful provincial respiratory syncytial virus prophylaxis program

Canadian Journal of Cardiology

Volumn 23, Issue 6, 2007, Pages 463-466

  Warren, Andrew ^a,b   Langley, Joanne M ^a,b   Thomas, Wanda ^c   Scott, Jeff ^a,d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

^c Nova Scotia Provincial Blood Coordinating Program   (Canada)

^d Nova Scotia Department of Health   (Canada)

Author keywords

Congenital heart disease; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHILD HEALTH CARE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONGENITAL HEART DISEASE; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PASSIVE IMMUNIZATION; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; VIRUS INFECTION; CANADA; CONGENITAL HEART MALFORMATION; FACTUAL DATABASE; FEMALE; IMMUNOLOGY; INFANT; MALE; NEWBORN; OUTCOME ASSESSMENT;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CANADA; CHILD HEALTH SERVICES; DATABASES, FACTUAL; DELIVERY OF HEALTH CARE; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 34250672029     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70785-7     Document Type: Article

References (11)

1. Langley JM, LeBlanc JC, Smith B, Wang EE. Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000. J Infect Dis 2003;188:1764-7.
2. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-54.
3. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: Postoperative course and outcome. Crit Care Med 1999;27:1974-81.
4. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: A contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8.
5. Feltes TF, Cabalka AK, Meissner HC, et al; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
6. Infectious Diseases and Immunization Committee, Canadian Paediatric Society (CPS). Use of palivizumab in children with congenital heart disease. Paediatr Child Health 2003;8:631-3.
7. National Advisory Committee on Immunization. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab). Can Commun Dis Rep 2003;29:1-15.
8. Bellavance M, Rohlicek CV, Bigras J-L, et al. Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice. Paediatr Child Health 2006;11:19-23.
9. Fenton C, Scott LJ, Plosker GL. Palivizumab: A review of its use as prophylaxis for serious respiratory syncytial virus infection. Paediatr Drugs 2004;6:177-97.
10. Strutton DR, Stang PE. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making. J Pediatr 2003;143(5 Suppl):S157-62.
11. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11.